Glucocorticoids are the first-line immunosuppressive treatment for feline immune-mediated thrombocytopenia (ITP), with additional agents selected based on treatment response. Azathioprine is absolutely contraindicated in cats and must never be used — it causes fatal myelosuppression in this species.Journal of Vete…

Immunosuppressive glucocorticoids form the foundation of feline ITP treatment. The 2024 ACVIM Consensus Statement on the Treatment of ITP in Dogs and Cats identifies glucocorticoids at immunosuppressive doses as first-line therapy for both species.Journal of Vete… The specific feline dosing protocol is not detailed in the consensus abstract, but glucocorticoid monotherapy carries a meaningful relapse risk — in the published feline case, relapse occurred within 3 weeks of initiating glucocorticoid treatment.Journal of Vete…

When glucocorticoids fail or relapse occurs, second-line immunosuppressive agents are added. The 2024 ACVIM consensus identifies modified cyclosporine and mycophenolate mofetil (MMF) as the appropriate second-line options in cats.Journal of Vete… Azathioprine, while listed as a second-line agent in dogs, is contraindicated in cats due to fatal myelosuppression and is explicitly excluded from feline protocols.Journal of Vete… Chlorambucil has been used in at least one refractory feline ITP case, though its efficacy was insufficient as a single agent in that patient.Journal of Vete…

MMF has documented use in refractory feline ITP. In the published case of a British Shorthair cat with primary ITP refractory to glucocorticoids and chlorambucil, MMF was used successfully following splenectomy and achieved remission sustained over 6 months.Journal of Vete… Specific feline MMF dosing for ITP is not established in the available literature.

Vincristine and human IV immunoglobulin (hIVIg) are adjunctive options for severe or refractory cases. Both are identified in the ACVIM consensus as part of the feline ITP treatment armamentarium, typically reserved for more severe presentations.Journal of Vete… Vincristine at 0.02 mg/kg IV is associated with faster platelet count recovery in dogs with ITP, though direct feline dosing data for ITP are not reported in the available literature.Journal of Vete…

Romiplostim represents an emerging option for life-threatening thrombocytopenia while definitive immunosuppression is being optimized. The first reported use of romiplostim in a cat with ITP demonstrated that it can be effective as a bridge therapy, though the efficacy of sustained use may be variable.Journal of Vete… Specific dosing protocols for feline romiplostim use in ITP are not yet established in the veterinary literature.

Splenectomy is reserved for refractory cases. In the published feline case, splenectomy was performed after failure of glucocorticoids, chlorambucil, and romiplostim, and was part of the combination approach that ultimately achieved remission.Journal of Vete… The ACVIM consensus confirms splenectomy is a refractory-case option in both dogs and cats, with ongoing debate about optimal patient selection and timing.Journal of Vete…

Feline ITP carries substantial morbidity and mortality risk. Mortality rates for ITP in dogs and cats range from 10% to 30%, with treatment-associated morbidity from immunosuppression contributing alongside refractory hemorrhage.Journal of Vete…

Would you like guidance on glucocorticoid tapering protocols and how to time the introduction of second-line agents in cats that respond initially but relapse?